key: cord-1016818-0tfm5gcf
authors: Kawasuji, Hitoshi; Morinaga, Yoshitomo; Tani, Hideki; Yoshida, Yoshihiro; Takegoshi, Yusuke; Kaneda, Makito; Murai, Yushi; Kimoto, Kou; Ueno, Akitoshi; Miyajima, Yuki; Fukui, Yasutaka; Kimura, Miyuki; Yamada, Hiroshi; Sakamaki, Ippei; Yamamoto, Yoshihiro
title: SARS‐CoV‐2 RNAemia with a higher nasopharyngeal viral load is strongly associated with disease severity and mortality in patients with COVID‐19
date: 2021-08-25
journal: J Med Virol
DOI: 10.1002/jmv.27282
sha: a37aefad024807ee2823ac698f85758e3507938b
doc_id: 1016818
cord_uid: 0tfm5gcf

This study aimed to determine the frequency of SARS‐CoV‐2 RNA in serum and its association with the clinical severity of COVID‐19. This retrospective cohort study performed at Toyama University Hospital included consecutive patients with confirmed COVID‐19. The prevalence of SARS‐CoV‐2 RNAemia and the strength of its association with clinical severity variables were examined. Fifty‐six patients were included in this study. RNAemia was detected in 19.6% (11/56) patients on admission, and subsequently in 1.0% (1/25), 50.0% (6/12), and 100.0% (4/4) moderate, severe, and critically ill patients, respectively. Patients with RNAemia required more frequent oxygen supplementation (90.0% vs. 13.3%), ICU admission (81.8% vs. 6.7%), and invasive mechanical ventilation (27.3% vs. 0.0%). Among patients with RNAemia, the median viral loads of nasopharyngeal (NP) swabs that were collected around the same time as the serum sample were significantly higher in critically ill (5.4 log(10) copies/μl; interquartile range [IQR]: 4.2–6.3) than in moderate‐severe cases (2.6 log(10) copies/μl; [IQR: 1.1–4.5]; p = 0.030) and were significantly higher in nonsurvivors (6.2 log(10) copies/μl [IQR: 6.0–6.5]) than in survivors (3.9 log(10) copies/μl [IQR: 1.6–4.6]; p = 0.045). This study demonstrated a relatively high proportion of SARS‐CoV‐2 RNAemia and an association between RNAemia and clinical severity. Moreover, among the patients with RNAemia, the viral loads of NP swabs were correlated with disease severity and mortality, suggesting the potential utility of combining serum testing with NP tests as a prognostic indicator for COVID‐19, with higher quality than each separate test.

Knowledge of the viral load dynamics of SARS-CoV-2 in nasopharyngeal (NP) swabs and other tissues plays an important role in understanding the pathogenesis, transmission, and management of patients with coronavirus disease . 1 Previous studies have found that the viral load in NP swab specimens peaks around the time of symptom onset and generally becomes undetectable about 2 or 3 weeks after symptom onset 2,3 ; however, there is evidence of prolonged virus detection in elderly patients, 4 with previous studies showing that the viral load in the respiratory specimens of symptomatic patients was similar to that of asymptomatic patients, 5 thus implying that the viral load in respiratory specimens may not objectively reflect disease severity. 6 On the other hand, some studies have reported that a high viral load in NP swabs was an independent risk factor for intubation and/or death. 7, 8 Thus, the real impact of initial SARS-CoV-2 viral load in NP swabs on clinical outcomes is not been clearly elucidated.

Previous studies have indicated that SARS-CoV-2 RNA may also be detected in plasma and serum, 9, 10 and serum SARS-CoV-2 viral RNA (termed RNAemia by the authors in a recent study) was detected in 15% of COVID-19 patients. 11 Recent studies demonstrated that RNAemia is associated with disease severity and unfavorable clinical outcomes. 12, 13 This suggests that extra-respiratory spread of SARS-CoV-2 contributes to systemic inflammatory responses, which are an important factor in the systemic pathogenesis of COVID-19, including thrombosis and coagulopathy. 13, 14 However, the clinical implication with SARS-CoV-2 RNAemia detection have not been completely clarified and information regarding the use of NP swabs and blood samples to improve patient management is insufficient.

In this study, we conducted a retrospective, monocentric cohort study of consecutive COVID-19 patients to investigate the frequency of SARS-CoV-2 RNA in serum and its association with the clinical severity of COVID-19.

This cohort study enrolled consecutive patients who were admitted to and/or from whom viral load measurements and blood tests were conducted at Toyama University Hospital with confirmed COVID-19 from April 13, 2020, to September 28, 2020, were tested for SARS-CoV-2 RNA in serum collected at the initial visit. NP samples that were collected approximately at the same time of serum collection around admission were included in the study as paired NP samples if residual tested serum was collected within seven days before or after NP collection. Given that viral culture was not performed to determine virus viability, the presence of viral RNA in serum is referred to as RNAemia instead of viremia.

A retrospective chart review was performed for all individuals in the study to identify basic demographic data, medical history, clinical presentation, and laboratory test results on hospital admission. The collected outcome data included the need for oxygen supplementation, admission to an intensive care unit (ICU), invasive mechanical ventilation, and all-cause mortality. Chest computed tomography was carried out in all patients around admission and severity was divided into five categories: asymptomatic, mild (symptomatic patients without pneumonia), moderate (pneumonia patients without required oxygen supplementation), severe (required oxygen supplementation), and critically ill (requiring invasive mechanical ventilation, shock, and/or multiple organ dysfunction). The sample size was based on a convenience set of all available clinical samples, without formal power calculations. 15 Quantification quality was controlled using AcroMetrix COVID-19 RNA Control (Thermo Fisher Scientific). The detection limit was approximately 0.4 copies/µl (two copies/5 µl). When undetectable, viral load data were hypothetically calculated as −0.5 log 10 copies/µl.

Continuous and categorical variables are presented as median (interquartile range [IQR]) and n (%), respectively. We used the Mann-Whitney U test, χ 2 test, or Fisher's exact test to compare the differences between patients with and without RNAemia. In all analyses, we preliminarily confirmed the effect of multicollinearity of the covariates used in the statistical analysis. Univariate logistic regression analysis was used to investigate variables potentially asso- The numbers of asymptomatic, mild, moderate, severe, and critically ill cases were 6, 9, 25, 12, and 4, respectively. Figure 1 shows the proportion of patients with detectable RNAemia, stratified by severity. The proportions of patients with RNAemia in moderate, severe, and critically ill cases were 1.0% (1/25), 50.0% (6/12), and 100.0% (4/4), respectively, but there were no asymptomatic and mild cases.

In terms of clinical outcomes, patients with RNAemia required more frequent oxygen supplementation (90.0% vs. 13.3%;

p < 0.0001) and ICU admission (81.8% vs. 6.7%; p < 0.0001), and also required invasive mechanical ventilation (27.3% vs. 0.0%; p < 0.0001).

In addition, RNAemia was independently associated with an increased risk of requiring more frequent oxygen supplementation and ICU admission in univariate and multivariate conditional logistic regression analyses (Tables 1 and 2 ). RNAemia was also associated with required invasive mechanical ventilation in univariate analysis, but multivariate conditional logistic regression analysis could not be conducted due to complete separation because of strong relationships. In-hospital mortality was more frequent in patients with SARS- studies have reported different rates of SARS-CoV-2 detection in serum (ranging from 10.4% to 74.1%), 1, 8, 9, [16] [17] [18] whereas other studies did not find any patients or reported only 1% of RNAemia. 16, 17 However, a direct comparison of these results is difficult because of the use of different testing protocols, including differences in specimen extraction volumes, sample types (plasma, serum, and whole blood), viral genomic targets (N, S, E genes, or ORF1ab region), variable timing of blood collection, and different patient populations. 9 Regarding the clinical importance of the presence of SARS-CoV-2 RNAemia, our results are consistent with previous reports, suggesting an association with ICU admission, invasive mechanical ventilation, and mortality. 19, 20 However, the association between viral load in respiratory specimens and severity remains unclear and controversial in the literature. Multiple case series have reported that the viral load in asymptomatic patients is as high as that in asymptomatic patients, 5, 18 while recent studies have found that NP viral load at admission is independently correlated with the risk of intubation and in-hospital mortality. 8 This study has several limitations inherent to its small sample size, retrospective design, and potential for confounding the detection of SARS-CoV-2 RNA from the serum, NP viral load, and clinical conditions that cannot be excluded. In addition, we did not conduct multivariate or age-adjusted analyses owing to the strong multicollinearity between variables and the small sample size. Longitudinal analyses were also not performed because viral load dynamics could be modified by the treatment, including combinations of antivirals and antibiotics during hospitalization.

In conclusion, this study demonstrated a relatively high overall proportion of detectable SARS-CoV-2 RNAemia as well as a strong association between serum viral detection and severe clinical disease, including the need for oxygen supplementation and ICU admission, invasive mechanical ventilation, and the likelihood of in-hospital mortality. In addition, among the patients with RNAemia, the viral loads of NP swabs were significantly higher in critically ill and nonsurvivor cases than in moderate-severe and survivor cases. Further studies are required to investigate the prognostic potential of RNAemia and those combined with the viral load of NP 

SARS-CoV-2 RNAemia is associated with severe chronic underlying diseases but not with nasopharyngeal viral load

Transmissibility of COVID-19 depends on the viral load around onset in adult and symptomatic patients

Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening

Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19)

Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility

Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019

Impact of viral load at admission on the development of respiratory failure in hospitalized patients with SARS-CoV-2 infection

SARS-CoV-2 viral load predicts COVID-19 mortality. The Lancet Respiratory Medicine

High frequency of SARS-CoV-2 RNAemia and association with severe disease

Detection of SARS-CoV-2 in different types of clinical specimens

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care

Quantitative assessment of SARS-CoV-2 RNAemia and outcome in patients with coronavirus disease 2019

Temporal kinetics of RNAemia and associated systemic cytokines in hospitalized COVID-19 patients

Development of genetic diagnostic methods for novel coronavirus 2019 (nCoV-2019) in Japan

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

A novel coronavirus from patients with pneumonia in China

SARS-CoV-2 detection, viral load and infectivity over the course of an infection

SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study

Highly sensitive quantification of plasma SARS-CoV-2 RNA shelds light on its potential clinical value

SARS-CoV-2 RNA in plasma is associated with ICU admission and mortality in patients hospitalized with COVID-19

Research and Development (AMED) under Grant JP20he0622035.The authors would like to thank Ai Kakumoto for her support in the COVID-19 testing.

The authors declare that there are no conflict of interests. 

The data that support the findings of this study are available from the corresponding author upon reasonable request.

http://orcid.org/0000-0003-2088-8724